MA34654B1 - Variants silencieux de fc d'anticorps anti-cd40 - Google Patents

Variants silencieux de fc d'anticorps anti-cd40

Info

Publication number
MA34654B1
MA34654B1 MA35885A MA35885A MA34654B1 MA 34654 B1 MA34654 B1 MA 34654B1 MA 35885 A MA35885 A MA 35885A MA 35885 A MA35885 A MA 35885A MA 34654 B1 MA34654 B1 MA 34654B1
Authority
MA
Morocco
Prior art keywords
antibodies
silent variants
silent
variants
transplant
Prior art date
Application number
MA35885A
Other languages
English (en)
Inventor
Christoph Heusser
James Rush
Karen Vincent
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44925566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34654(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA34654B1 publication Critical patent/MA34654B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

La présente invention concerne des variants silencieux de FC d'anticorps anti-CD40 et des compositions et des procédés d'utilisation desdits anticorps pour le traitement de troubles pathologiques, tels que des troubles auto-immuns et inflammatoires et/ou pour la prévention ou la réduction du risque du rejet de greffe dans une transplantation.
MA35885A 2010-11-15 2013-05-07 Variants silencieux de fc d'anticorps anti-cd40 MA34654B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41356710P 2010-11-15 2010-11-15
PCT/EP2011/070058 WO2012065950A1 (fr) 2010-11-15 2011-11-14 Variants silencieux de fc d'anticorps anti-cd40

Publications (1)

Publication Number Publication Date
MA34654B1 true MA34654B1 (fr) 2013-11-02

Family

ID=44925566

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35885A MA34654B1 (fr) 2010-11-15 2013-05-07 Variants silencieux de fc d'anticorps anti-cd40

Country Status (39)

Country Link
US (8) US8828396B2 (fr)
EP (4) EP2640749B1 (fr)
JP (1) JP5782132B2 (fr)
KR (1) KR101632775B1 (fr)
CN (2) CN105949314B (fr)
AR (2) AR083847A1 (fr)
AU (1) AU2011331288B2 (fr)
BR (1) BR112013011644B1 (fr)
CA (1) CA2815921C (fr)
CL (1) CL2013001124A1 (fr)
CO (1) CO6801629A2 (fr)
CR (1) CR20130222A (fr)
CU (1) CU24057B1 (fr)
CY (2) CY1119097T1 (fr)
DK (2) DK3502138T3 (fr)
EA (1) EA026133B1 (fr)
ES (2) ES2633817T3 (fr)
GT (1) GT201300128A (fr)
HR (2) HRP20171084T1 (fr)
HU (2) HUE034203T2 (fr)
IL (1) IL225719A (fr)
JO (1) JO3266B1 (fr)
LT (2) LT3502138T (fr)
MA (1) MA34654B1 (fr)
MX (1) MX336633B (fr)
MY (1) MY159316A (fr)
NZ (1) NZ609549A (fr)
PE (1) PE20140979A1 (fr)
PH (1) PH12013500973A1 (fr)
PL (2) PL3502138T3 (fr)
PT (2) PT3502138T (fr)
RS (2) RS56153B1 (fr)
SG (1) SG189928A1 (fr)
SI (2) SI3502138T1 (fr)
TW (2) TWI608016B (fr)
UA (1) UA112417C2 (fr)
UY (2) UY33728A (fr)
WO (1) WO2012065950A1 (fr)
ZA (1) ZA201302532B (fr)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3153526T3 (da) 2008-01-31 2020-12-14 Inst Nat Sante Rech Med Antistoffer mod human cd39 og anvendelse deraf til inhibering af aktivitet af t-regulatoriske celler
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
JP5458188B2 (ja) * 2011-02-17 2014-04-02 協和発酵キリン株式会社 抗ｃｄ４０抗体の高濃度製剤
HUE065915T2 (hu) 2011-03-11 2024-06-28 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antitestek és alkalmazásaik
BR112013026828A2 (pt) 2011-04-21 2016-11-29 Bristol Myers Squibb Co polipeptídeos de anticorpo que antagonizam cd40
CN113461819B (zh) 2011-04-29 2024-01-02 埃派斯进有限公司 抗-cd40抗体及其使用方法
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
AU2013337903B2 (en) 2012-10-30 2018-08-16 Apexigen, Inc. Anti-CD40 antibodies and methods of use
NZ710929A (en) 2013-03-15 2018-02-23 Novartis Ag Antibody drug conjugates
WO2015134988A1 (fr) 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Procédé d'utilisation de polypeptides d'anticorps qui sont des antagonistes de cd40 pour traiter une affection intestinale inflammatoire (aii)
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
KR20170040249A (ko) 2014-08-12 2017-04-12 노파르티스 아게 항-cdh6 항체 약물 접합체
IL250579B2 (en) 2014-10-10 2023-05-01 Innate Pharma blocking cd73
AU2015360502A1 (en) 2014-12-10 2017-06-29 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
GB201501613D0 (en) 2015-01-30 2015-03-18 Ucb Biopharma Sprl Treatment of autoimmune disorders with CD154 antibodies
EP3081942A1 (fr) * 2015-04-17 2016-10-19 Roche Diagniostics GmbH Liquide de transmission de pression pour analyseur cellulaire, analyseur cellulaire et procédé d'analyse d'un échantillon cellulaire liquide
US10174121B2 (en) 2015-05-29 2019-01-08 Abbvie, Inc. Anti-CD40 antibodies
WO2017040932A1 (fr) 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Anticorps humanisés anti-cd40 et leurs utilisations
WO2017044424A1 (fr) 2015-09-08 2017-03-16 Theripion, Inc. Polypeptides de fusion apoa-1 ainsi que compositions et procédés associés
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
CR20180177A (es) 2015-09-30 2018-06-22 Janssen Biotech Inc Anticuerpos agonistas que se unen específicamente a cd40 humana y método de uso
US11130817B2 (en) 2015-10-12 2021-09-28 Innate Pharma CD73 blocking agents
PL3413894T3 (pl) 2016-02-10 2020-10-05 Novartis Ag Zastosowanie inhibitorów aktywności lub czynności PI3K do leczenia pierwotnego zespołu Sjögrena
WO2017153433A1 (fr) 2016-03-08 2017-09-14 Innate Pharma Anticorps neutralisant les siglecs
US20190071514A1 (en) 2016-03-14 2019-03-07 Innate Pharma Anti-cd39 antibodies
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
WO2018065552A1 (fr) 2016-10-06 2018-04-12 Innate Pharma Anticorps anti-cd39
WO2018083080A2 (fr) 2016-11-04 2018-05-11 Innate Pharma Ligand de nkp46
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018138032A2 (fr) 2017-01-24 2018-08-02 Innate Pharma Agents de liaison nkp46
US20200023071A1 (en) 2017-02-06 2020-01-23 Innate Pharma Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
CN110382544B (zh) 2017-03-16 2023-12-22 先天制药公司 用于治疗癌症的组合物和方法
CN110582264B (zh) * 2017-03-26 2022-11-11 V·R·斯塔福德 眼睑皮肤状况的处理方法
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2018185618A1 (fr) 2017-04-03 2018-10-11 Novartis Ag Conjugués de médicament-anticorps anti-cdh6 et combinaisons d'anticorps anti-gitr et méthodes de traitement
WO2018217976A1 (fr) 2017-05-25 2018-11-29 Bristol-Myers Squibb Company Anticorps monoclonaux antagonistes anti-cd40 et leurs utilisations
KR20200012907A (ko) * 2017-05-25 2020-02-05 브리스톨-마이어스 스큅 컴퍼니 변형된 IgG1 Fc 도메인 및 그와의 항-CD40 도메인 항체 융합체
JP2020521788A (ja) * 2017-06-02 2020-07-27 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 免疫アゴニストの投与経路
AU2018298676A1 (en) 2017-07-10 2019-12-19 Innate Pharma Siglec-9-neutralizing antibodies
AU2018298673A1 (en) 2017-07-10 2019-12-19 Innate Pharma Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer
EP3684813B1 (fr) * 2017-09-19 2025-10-08 MAB Discovery GmbH Anticorps cd40 agonistes
AU2018361743A1 (en) * 2017-11-03 2020-04-09 Novartis Ag Anti-CD40 antibodies for use in treatment of Sjogren's syndrome
JP7685835B2 (ja) 2017-12-01 2025-05-30 ノバルティス アーゲー ポリオーマウイルス中和抗体
JP6861301B2 (ja) * 2018-04-13 2021-04-21 ノバルティス アーゲー 移植片拒絶の予防に使用するための抗ｃｄ４０抗体
IT201800004853A1 (it) 2018-04-24 2019-10-24 Metodi per trattare il cancro
US11932681B2 (en) 2018-05-31 2024-03-19 Novartis Ag Hepatitis B antibodies
CN112638375A (zh) 2018-06-15 2021-04-09 旗舰创业创新五公司 通过后细胞信号传导因子的调节来增加免疫活性
MX2020012107A (es) 2018-06-18 2021-01-29 Innate Pharma Composiciones y procedimientos para el tratamiento del cancer.
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
WO2019246312A1 (fr) 2018-06-20 2019-12-26 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un immunomodulateur
WO2020053742A2 (fr) 2018-09-10 2020-03-19 Novartis Ag Anticorps peptidiques anti-hla-vhb
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
TW202039554A (zh) 2018-12-19 2020-11-01 瑞士商諾華公司 抗ＴＮＦ－α抗體
EP3902829A2 (fr) 2018-12-26 2021-11-03 Innate Pharma Anticorps neutralisant le récepteur de type immunoglobuline des leucocytes
WO2020144605A1 (fr) * 2019-01-11 2020-07-16 Novartis Ag Anticorps anti-cd40 destinés à être utilisés dans le traitement de l'hidrosadénite suppurée
SG11202111106WA (en) 2019-04-23 2021-11-29 Innate Pharma Cd73 blocking antibodies
WO2020227159A2 (fr) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Métodes de modulation de l'activité immunitaire
WO2020225736A1 (fr) * 2019-05-08 2020-11-12 Novartis Ag Anticorps anti-cd40 destinés à être utilisés dans le traitement du t1dm et de l'insulite
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
EA202193345A1 (ru) 2019-06-12 2022-03-16 Новартис Аг Антитела к рецептору-1 натрийуретического пептида и способы их применения
AU2020300002A1 (en) * 2019-07-01 2022-02-24 Tonix Pharma Limited Anti-CD154 antibodies and uses thereof
MX2022003009A (es) 2019-09-11 2022-06-14 Novartis Ag Metodo para prevenir trastornos asociados a virus humanos en pacientes.
MX2022003192A (es) 2019-09-18 2022-04-11 Novartis Ag Proteinas de fusion nkg2d y sus usos.
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
CN115397394A (zh) * 2020-01-31 2022-11-25 赛诺菲 抗体的肺部递送
KR20220146530A (ko) 2020-02-27 2022-11-01 노파르티스 아게 키메라 항원 수용체-발현 세포의 제조 방법
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
JP2023532339A (ja) 2020-06-29 2023-07-27 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用
WO2022033978A2 (fr) 2020-08-13 2022-02-17 Innate Pharma Procédés de traitement du cancer utilisant des anticorps anti-cd73
US20230302155A1 (en) 2020-08-21 2023-09-28 Novartis Ag Compositions and methods for in vivo generation of car expressing cells
CN116234909A (zh) * 2020-08-21 2023-06-06 上海药明生物技术有限公司 Cd40激动剂抗体和使用方法
JP2023547499A (ja) 2020-11-06 2023-11-10 ノバルティス アーゲー 抗体Ｆｃ変異体
EP4259661A1 (fr) 2020-12-14 2023-10-18 Novartis AG Agents d'inversion de liaison pour anticorps anti-récepteur 1 du peptide natriurétique (npr1) et leurs utilisations
US20250002587A1 (en) * 2021-01-26 2025-01-02 The Regents Of The University Of California Prevention of posterior capsular opacification (pco) with integrin avb8 blocking antibody
FI4284512T3 (fi) * 2021-01-28 2025-05-22 Regeneron Pharma Koostumuksia ja menetelmiä sytokiinien vapautumisoireyhtymän hoitamiseksi
JP2024512669A (ja) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
BR112023026111A2 (pt) * 2021-06-28 2024-03-05 Jiangsu Hengrui Pharmaceuticals Co Ltd Anticorpo anti-cd40, fragmento de ligação ao antígeno e uso médico do mesmo
US20240316104A1 (en) 2021-06-29 2024-09-26 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
JP2024531364A (ja) 2021-08-20 2024-08-29 ノバルティス アーゲー キメラ抗原受容体発現細胞を作製する方法
EP4393937A4 (fr) 2021-08-26 2025-12-31 Duality Biologics Shanghai Co Ltd Composé stéroïde et conjugué de celui-ci
EP4402174A1 (fr) 2021-09-17 2024-07-24 Novartis AG Méthodes de prévention du rejet de greffe dans une xénogreffe
US20240383994A1 (en) 2021-09-24 2024-11-21 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Anti-cd40 antibody and use thereof
JP2024538573A (ja) 2021-10-01 2024-10-23 マブ ディスカバリー ゲゼルシャフト ミット ベシュレンクテル ハフツング 免疫刺激剤としてのアゴニスト性ｃｄ４０抗体
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
WO2023187657A1 (fr) 2022-03-30 2023-10-05 Novartis Ag Méthodes de traitement de troubles à l'aide d'anticorps anti-récepteur du peptide natriurétique 1 (npr1)
EP4587047A1 (fr) 2022-09-15 2025-07-23 Novartis AG Traitement de troubles auto-immuns à l'aide d'une thérapie par récepteur antigénique chimérique
WO2024077191A1 (fr) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Molécules d'acide nucléique codant pour des trif et des polypeptides supplémentaires et leur utilisation dans le traitement du cancer
US20240190978A1 (en) 2022-11-15 2024-06-13 CSBioAsset LLC Compositions and methods for immunomodulatory bifunctional fusion molecules
WO2024140917A1 (fr) * 2022-12-28 2024-07-04 上海盛迪医药有限公司 Conjugué anticorps-médicament anti-cd40, son procédé de préparation et son utilisation médicale
WO2024151687A1 (fr) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Commutateurs génétiques et leur utilisation dans le traitement du cancer
EP4727973A1 (fr) 2023-06-16 2026-04-22 Regeneron Pharmaceuticals, Inc. Molécules de liaison à l'antigène bispécifiques cd40 x cd40 et leurs utilisations
WO2025023895A1 (fr) * 2023-07-26 2025-01-30 Db Biotech, A.S. Anticorps dirigé contre le composant c4d du complément
WO2025184567A1 (fr) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Procédés et compositions pour redosage d'un aav à l'aide d'un anticorps antagoniste anti-cd40 pour supprimer une réponse d'anticorps anti-aav hôte
WO2025184603A2 (fr) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Utilisation d'inhibiteurs de cd40 pour inhiber une réponse immunitaire et permettre une administration et une réadministration d'immunogène
WO2025233264A1 (fr) 2024-05-07 2025-11-13 Innate Pharma Utilisation d'agents bloquant le cd73 en association avec des engageurs de lymphocytes t anti-cd20 x cd3
WO2025233266A1 (fr) 2024-05-07 2025-11-13 Innate Pharma Utilisation d'agents bloquant le cd39 en association avec des engageurs de lymphocytes t anti-cd20 x cd3

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US106A (en) 1915-08-24 Specipication
US4766A (en) 1846-09-19 Stbaw-cutter
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (fr) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Composition à action prolongée
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
CA1292686C (fr) 1986-10-27 1991-12-03 Ze'ev Shaked Compositions pharmaceutiques d'interleukine-2 recombinante et procede de fabrication
CA1294215C (fr) 1986-10-27 1992-01-14 Ze'ev Shaked Compositions pharmaceutiques d'interferon beta recombinant et methodes de formulation
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
ES2211884T3 (es) 1993-10-01 2004-07-16 Immunex Corporation Anticuerpos contra el cd40.
EP0751781B1 (fr) 1993-12-23 2004-05-26 Immunex Corporation Utilisation d'anticorps monoclonaux ou de ligands oligomeriques solubles pour la preparation d'un medicament pour le traitement de maladies neoplasiques
WO1995023512A1 (fr) 1994-03-03 1995-09-08 Alexion Pharmaceuticals, Inc. Genes et proteines de fusion inhibant le complement terminal
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
CA2226575C (fr) 1995-07-27 2011-10-18 Genentech, Inc. Formulation de proteine lyophilisee isotonique et stable
EP0999853B1 (fr) 1997-06-13 2003-01-02 Genentech, Inc. Formulation stabilisee renfermant un anticorps
WO1998058672A1 (fr) 1997-06-20 1998-12-30 Biogen, Inc. Therapie par blocage des cellules cd154 contre le syndrome inhibiteur de proteines therapeutiques
CA2304808C (fr) 1997-09-23 2011-03-22 Michael Tschope Formulations liquides d'interferon .beta.
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US20020006901A1 (en) 1999-02-05 2002-01-17 Aldo T. Iacono Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
WO2001034649A2 (fr) 1999-11-09 2001-05-17 Chiron Corporation Compositions et methodes de traitement de maladies auto-immunes et des rejets de greffon
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
AU2001259215A1 (en) 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
SG136804A1 (en) 2000-07-12 2007-11-29 Idec Pharma Corp Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
CA2422076A1 (fr) 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Polytherapie pour le traitement de maladies auto-immunes utilisant une combinaison d'anticorps d'immunoregulation/de depletion de cellules b
JP4202127B2 (ja) 2000-10-02 2008-12-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法
JP4463475B2 (ja) 2001-01-31 2010-05-19 バイオジェン アイデック インコーポレイテッド 腫瘍疾患の治療における免疫調節性抗体の使用
IL157946A0 (en) 2001-04-02 2004-03-28 Genentech Inc Combination therapy
PT1391464E (pt) 2001-04-27 2007-11-15 Kirin Pharma Kk Anticorpo monoclonal anti-cd40
WO2003029296A1 (fr) 2001-10-02 2003-04-10 Chiron Corporation Anticorps humains diriges contre le cd40
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
AU2002346581A1 (en) 2001-11-26 2003-06-10 Chiron Corporation Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
US20080199471A1 (en) * 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
RU2358763C2 (ru) 2003-02-10 2009-06-20 Элан Фармасьютикалз, Инк. Композиции иммуноглобулина и способ их получения
CA2544951A1 (fr) 2003-11-04 2005-05-19 Chiron Corporation Utilisation d'anticorps monoclonaux antagonistes anti-cd40 pour le traitement de myelome multiple
EP1680141B8 (fr) 2003-11-04 2011-01-12 Novartis Vaccines and Diagnostics, Inc. Procedes therapeutiques de tumeurs solides exprimant l'antigene de surface cellulaire cd40
PT1694360E (pt) * 2003-11-04 2010-12-13 Novartis Vaccines & Diagnostic Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento de doenças auto-imunes e inflamatórias e da rejeição ao transplante de orgãos
ATE474598T1 (de) 2003-11-04 2010-08-15 Novartis Vaccines & Diagnostic Verwendung von antagonisten-anti-cd40-antikörpern zur behandlung von chronisch lymphozytischer leukämie
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
EP1844815B1 (fr) 2003-11-04 2011-09-14 Novartis Vaccines and Diagnostics, Inc. Combination d'anticorps anti-CD20 et d'anticorps anti-CD40 pour le traitment des cancers liés aux lymphocytes B
BRPI0417266B8 (pt) 2003-12-25 2021-05-25 Kyowa Hakko Kirin Co Ltd anticorpo monoclonal, seu uso e composição farmacêutica
CN101014386A (zh) 2004-04-27 2007-08-08 诺华疫苗和诊断公司 拮抗性抗－cd40单克隆抗体及其使用方法
US20080057070A1 (en) * 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
WO2006125117A2 (fr) 2005-05-18 2006-11-23 Novartis Ag Procedes de diagnostic et de traitement de maladies ayant une composante auto-immune et/ou inflammatoire
JP2009513712A (ja) 2005-11-01 2009-04-02 ノバルティス アーゲー 抗ｃｄ４０抗体の使用
RU2426744C2 (ru) * 2005-12-16 2011-08-20 Дженентек, Инк. Антитела к ox40l и способы их применения
MX2008013508A (es) 2006-04-21 2008-10-31 Novartis Ag Composiciones farmaceuticas de anticuerpos antagonistas anti-cd40.
EP1854810A1 (fr) 2006-05-09 2007-11-14 PanGenetics B.V. Anticorps monoclonal anti CD40 humain déimmunisé et antagoniste dérivé de l'anticorps ch5D12
KR20090027227A (ko) * 2006-06-06 2009-03-16 제넨테크, 인크. 항-ｄｌｌ4 항체 및 이의 사용 방법
SI2550972T1 (en) * 2007-04-02 2018-05-31 Genentech, Inc. A Klotho-beta agonist antibody for use in the treatment of diabetes mellitus or insulin resistance
EP2137325A1 (fr) * 2007-04-02 2009-12-30 Genentech, Inc. Marqueurs biologiques prédictifs de la réaction de la polyarthrite rhumatoïde aux antagonistes de lymphocytes b
CA2693053C (fr) * 2007-05-30 2021-01-05 Xencor, Inc. Procedes et compositions permettant l'inhibition de cellules d'expression du cd32b
AU2009333580B2 (en) * 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
CA2759146C (fr) * 2009-04-20 2017-06-13 Kyowa Kirin Co., Ltd. Agoniste de l'anticorps anti-cd40
AR083847A1 (es) * 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
BR112015023547B8 (pt) 2013-03-15 2022-09-27 Synaptive Medical Inc Montagem de braço automatizado para uso usado durante um procedimento médico sobre uma parte anatômica

Also Published As

Publication number Publication date
RS63094B1 (sr) 2022-04-29
UY39292A (es) 2021-07-30
US20240228640A9 (en) 2024-07-11
GT201300128A (es) 2015-06-02
PT2640749T (pt) 2017-07-25
CR20130222A (es) 2013-06-28
CN105949314B (zh) 2021-04-09
HUE034203T2 (en) 2018-01-29
DK3502138T3 (da) 2022-04-19
EA026133B1 (ru) 2017-03-31
SI3502138T1 (sl) 2022-05-31
CY1119097T1 (el) 2018-01-10
ZA201302532B (en) 2014-09-25
US20160152721A1 (en) 2016-06-02
CU24057B1 (es) 2014-12-26
EP3502138A1 (fr) 2019-06-26
CN103209996B (zh) 2016-07-20
BR112013011644B1 (pt) 2022-02-22
MX2013005477A (es) 2013-06-12
CA2815921A1 (fr) 2012-05-24
EP3222636A1 (fr) 2017-09-27
AU2011331288B2 (en) 2014-09-11
JP2014500720A (ja) 2014-01-16
US9688768B2 (en) 2017-06-27
TWI531581B (zh) 2016-05-01
JO3266B1 (ar) 2018-09-16
CO6801629A2 (es) 2013-11-29
LT3502138T (lt) 2022-04-11
LT2640749T (lt) 2017-07-10
ES2911460T3 (es) 2022-05-19
IL225719A (en) 2017-09-28
US20240132606A1 (en) 2024-04-25
CU20130071A7 (es) 2013-09-27
UA112417C2 (uk) 2016-09-12
EP3502138B1 (fr) 2022-01-19
JP5782132B2 (ja) 2015-09-24
PL2640749T3 (pl) 2017-09-29
HRP20220413T1 (hr) 2022-05-27
TW201623335A (zh) 2016-07-01
WO2012065950A1 (fr) 2012-05-24
US20200087409A1 (en) 2020-03-19
PE20140979A1 (es) 2014-08-09
KR101632775B1 (ko) 2016-06-22
EP2640749A1 (fr) 2013-09-25
CN103209996A (zh) 2013-07-17
KR20130080856A (ko) 2013-07-15
US8828396B2 (en) 2014-09-09
TWI608016B (zh) 2017-12-11
HUE058015T2 (hu) 2022-06-28
PT3502138T (pt) 2022-04-06
RS56153B1 (sr) 2017-11-30
CL2013001124A1 (es) 2014-07-04
IL225719A0 (en) 2013-06-27
US11124578B2 (en) 2021-09-21
MY159316A (en) 2016-12-30
HRP20171084T1 (hr) 2017-10-06
US20140341898A1 (en) 2014-11-20
EP3502138B9 (fr) 2022-03-09
SG189928A1 (en) 2013-06-28
ES2633817T3 (es) 2017-09-25
CN105949314A (zh) 2016-09-21
BR112013011644A2 (pt) 2016-08-02
AR083847A1 (es) 2013-03-27
AU2011331288A1 (en) 2013-05-02
DK2640749T3 (en) 2017-07-31
US20120121585A1 (en) 2012-05-17
SI2640749T1 (sl) 2017-07-31
EP2640749B1 (fr) 2017-04-19
NZ609549A (en) 2015-05-29
UY33728A (es) 2012-06-29
PH12013500973A1 (en) 2013-07-08
CA2815921C (fr) 2021-07-06
US9221913B2 (en) 2015-12-29
US10323096B2 (en) 2019-06-18
EP4023676A1 (fr) 2022-07-06
PL3502138T3 (pl) 2022-05-02
EA201390725A1 (ru) 2013-09-30
TW201305208A (zh) 2013-02-01
US9828433B2 (en) 2017-11-28
US20220204635A1 (en) 2022-06-30
AR122999A2 (es) 2022-10-19
MX336633B (es) 2016-01-26
US20170267772A1 (en) 2017-09-21
CY1125252T1 (el) 2024-12-13
US20180118843A1 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
MA34654B1 (fr) Variants silencieux de fc d'anticorps anti-cd40
MA33256B1 (fr) Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
MA35661B1 (fr) Inhibiteurs de pak pour le traitement de troubles de prolifération cellulaire
MA31667B1 (fr) Induction dun phenotype tolerogene dans des cellules dendritiques matures
MA32471B1 (fr) Composés de borates esters et compositions pharmaceutiques contenant des composés
MA35365B1 (fr) Pyrimidines annelées substituées et leur utilisation
MA39211A1 (fr) Composés tricycliques comme agents anti-cancers
MA31795B1 (fr) Molécules et méthodes pour moduler un constituant de complément
MA32035B1 (fr) Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4
MA33349B1 (fr) Compositions pharmaceutiques solides et procedes pour leur production
MA34248B1 (fr) 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA34641B1 (fr) Anticorps anti-il-23
MA45504A1 (fr) Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives
EP2493930A4 (fr) Compositions et méthodes pour le traitement de troubles inflammatoires
EP2726509A4 (fr) Utilisation d'anticorps agonistes anti-cd83 pour le traitement de maladies auto-immunes
EP2766012A4 (fr) Compositions utiles pour le traitement d'une néphropathie et leurs procédés de préparation
MA34541B1 (fr) Compositions d'anticorps et procédés d'utilisation
MA20150279A1 (fr) (r)-nifuratel, son utilisation pour le traitement d'infections et synthèse de (r) et (s)-nifuratel
MA34175B1 (fr) Anticorps anti-cxcr4 humanisés pour le traitement de cancer
TN2014000195A1 (fr) 2-thiopyrimidinones
MA43113B1 (fr) Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci
MA33839B1 (fr) Compositions et procédés destinés à diagnostiquer et à traiter des tumeurs
TN2011000669A1 (fr) L-serine pour son utilisation en tant que medicament pour prevenir et/ou traiter une reaction inflammatoire de la peau
CA2777928C (fr) Polymorphisme genetique dans la degenerescence maculaire liee a l'age